MetaCap

Adaptive Biotechnologies (ADPT) vs Twist Bioscience (TWST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Twist Bioscience (TWST) has outperformed Adaptive Biotechnologies (ADPT) over the past year, gaining 261.8% versus a gain of 50.1%. Over five years, TWST leads with a +8.8% price change compared with -0.7% for ADPT. Twist Bioscience is the larger company by market cap ($7.04 billion vs $4.52 billion), about 1.6 times the size, while Adaptive Biotechnologies is growing revenue faster (+54.8% vs +22.0%).

Adaptive Biotechnologies converts more of its revenue into profit, with a net margin of -21.5% versus -28.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADPT+50.08%TWST+261.76%
+650%+292%-66%
Nov 21, 20251 yearNov 20, 2026
ADPT+2.12%TWST-6.60%
+79%-10%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADPT versus TWST key metrics
MetricADPTTWST
Share price$27.93$103.32
Market cap$4.52B$7.04B
1-day change-0.43%-7.44%
YTD return+71.98%+225.73%
1-year return+50.08%+261.76%
5-year return-0.68%+8.77%
EPS (TTM)$-0.45$-2.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$276.98M$459.43M
Revenue growth (YoY)+54.77%+22.00%
Net income (latest FY)$-59.50M$-130.20M
Gross margin74.24%52.41%
Operating margin-20.62%-30.35%
Net margin-21.48%-28.34%
52-week high$32.21$219.71
52-week low$12.00$28.27
Distance from 52-week high-13.29%-52.97%
Analyst consensusstrong_buybuy
Avg. price target upside+21.23%+24.68%
Average volume2.20M2.49M
Shares outstanding161.88M68.18M
Employees6241,080
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TWST has outperformed ADPT by 211.7 percentage points over the past year.
  • Adaptive Biotechnologies is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -28.3 cents for Twist Bioscience.
  • Adaptive Biotechnologies grew revenue faster in its latest fiscal year (+54.77% vs +22.00%).

About Adaptive Biotechnologies

ADPT stock →

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees

About Twist Bioscience

TWST stock →

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,080 employees

ADPT vs TWST FAQ

Which is bigger, Adaptive Biotechnologies or Twist Bioscience?

Twist Bioscience (TWST) is larger, with a market capitalization of $7.04B compared with $4.52B for Adaptive Biotechnologies (ADPT).

Which stock has performed better over the past year, ADPT or TWST?

TWST returned +261.76% over the past 12 months, compared with +50.08% for ADPT (price return, excluding dividends). Past performance does not predict future results.

Are Adaptive Biotechnologies and Twist Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons